论文部分内容阅读
目前已经证实重组人促红细胞生成素(rHuDPO)是一种治疗血透(HD)病人贫血的有效药物。但未见其对CAPD病人贫血疗效的有关报告。为了探索CAPD病人腹腔内应用EPO的可行性,作者对一组CAPD病人分别行静脉(IV)、皮下(SC)、腹腔(IP)rHuEPD一次给药的药物动力学研究。病人及方法 CAPD患者8例(男女各4例),平均62岁,行CAPD7～70个月,近6个月无腹膜炎发生,所有患者均接受3次r—HuEPO治疗。每次间隔至少4周。剂量:IV120u/kg,IP50000U,SC120U/Kg。对行IV及IP者于注射后24h,行SC者于注射后96h取血。低温分离血浆保存,待测EPO。整个研究过程CAPD照常进行。使用1.36％1葡萄糖透析
It has been demonstrated that recombinant human erythropoietin (rHuDPO) is a potent drug for the treatment of anemia in hemodialysis (HD) patients. But did not see its effect on anemia in patients with CAPD reports. In order to explore the feasibility of intra-peritoneal application of EPO in patients with CAPD, a pharmacokinetic study of one-time intravenous (IV), subcutaneous (SC) and intraperitoneal (IP) rHuEPD in a group of CAPD patients was conducted. Patients and Methods CAPD patients 8 cases (4 males and 4 females), average 62 years old, the CAPD 7 to 70 months, nearly 6 months without peritonitis, all patients received three r-HuEPO treatment. At least 4 weeks apart. Dose: IV120u / kg, IP50000U, SC120U / Kg. Line IV and IP in the injection after 24h, SC line at 96h after injection of blood. Plasma cryopreservation, EPO to be tested. CAPD throughout the research process as usual. 1.36% 1 glucose dialysis was used